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htotal of 811 abstracts were submitted in the area of
ardiac Function and Heart Failure. These are shown by
ub-topic in Figure 1. Each abstract was evaluated by 5 to 7
eviewers, 281 were selected for presentation, and 19 are
ighlighted in the following review. The committee mem-
ers for Cardiac Function and Heart Failure included C.
oel Bairey Merz, James C. Fang, James A. Hill, Douglas
. Mann, and Christopher M. O’Connor.
ATE-BREAKING CLINICAL TRIALS
he late-breaking clinical trials sessions were extraordinarily
opular at this year’s meeting. Several of these presentations
nvolved treatment of patients with heart failure (HF).
yoblasts in HF. Two reports used skeletal myoblasts for
he treatment of ischemic cardiomyopathy. Myoblasts taken
rom patients’ own thigh muscles were cultured and ex-
anded over four to six weeks. In one report, the myoblasts
ere implanted through the epicardial surface at the time of
oronary bypass surgery. Results of this multicenter study
ere presented by Dr. Dib, and it was also in the program
s a poster (1). Twenty-two patients were studied. All of
hem had previous myocardial infarction (MI), had ejection
ractions (EFs) under 40%, and had been referred for
lective coronary bypass surgery. Each patient received 3 to
0 direct injections of skeletal myoblasts (GenVec Inc.,
aithersburg, Maryland) at the time of bypass grafting. The
nvestigators showed evidence of viability of the implanted
ellular grafts both by positron emission tomography and
agnetic resonance imaging. Twenty-one of the 22 patients
re still alive at the three-year follow-up, and the researchers
eported significant improvement in EF, from 22.9% to
4.6% in the cohort.
At that same late-breaking clinical trials session, there
as a report titled “Myocardial Repair by Percutaneous Cell
ransplantation of Autologous Skeletal Myoblasts,” but in
his case “as a Stand-alone Procedure in post-MI Chronic
F Patients.” This was presented by Dr. Serruys and
olleagues from the Netherlands and various European sites.
he study enrolled 15 patients, who were an average of six
ears from a previous MI. The patients’ skeletal myoblasts
ere expanded using the Bioheart Inc. (Sunrise, Florida)
ethod and delivered to the ventricular wall through the
ndocardial surface using a percutaneous, fluoroscopy-
uided, implantation catheter. The results show 13 patients
till living at one-year after the procedure. The left ventric-
lar EF in this stand-alone procedure improved from 34.4%
o 36.6%, and the wall motion score improved from 3 to 2.7,m
From the Division of Cardiovascular Medicine, University of Florida College of
edicine, Gainesville, Florida.hich was statistically significant. One patient had new
pisodes of paroxysmal ventricular tachycardia at one week
nd two other patients developed ventricular tachycardia at
wo weeks. Following the presentation, the discussant, Dr.
ay Edelberg of New York, raised the possibility that
ost-procedure arrhythmias might be related to something
n the medium used to culture and expand the myoblasts
ather than to a direct arrhythmic effect of the implanted
ells themselves.
edications in HF. Drs. Teerlink and McMurray re-
orted on a trial in the area of novel medications for HF.
ecause various animal and preclinical studies have indi-
ated that circulating endothelin-1 is a potent vasoconstric-
or and that endothelin receptor blockade is beneficial in
F (2), Drs. Teerlink, McMurray, and colleagues evaluated
he endothelin receptor blocker tezosentan in acute HF.
heir results were combined from two different trials, titled
he VERITAS (Value of endothelin receptor inhibition
ith tezosentan in acute heart failure studies). These were
ulticenter, double-blind, placebo-controlled, parallel
roup designs and included a total of 1,449 patients with
cute HF, dyspnea at rest, and indication for intravenous
reatment. Therapy consisted of a 30-min tezosentan bolus
ollowed by a 24- to 72-h continuous infusion. The com-
osite end point for the study used a dyspnea score and the
ncidence of death or worsening HF at seven days. Inter-
stingly, the VERITAS studies were negative. The investi-
ators reported no benefit for the group treated with this
ndothelin receptor blocker, at least for the short-term
omposite end point that was used.
Another study that was accepted as a late-breaking
linical trial and utilized novel medical therapy was
EVIVE II (randomized evaluation of intravenous levosi-
endan efficacy versus placebo in the short-term treatment
f decompensated heart failure). This multicenter, interna-
ional, double-blind, randomized, placebo-controlled trial
as submitted by Dr. Packer and colleagues. Six-hundred
ubjects were recruited, and the report was selected for
ention at the “Meeting Highlights” session. However,
ata analysis was apparently delayed, so the investigators
ithdrew it, and the results were not presented. Stay tuned to
uture meetings.
evice therapies for HF. In the area of device therapies,
r. Bourge and colleagues presented the results of the
OMPASS-HF (Chronicle offers management to patients
ith advanced signs and symptoms of heart failure) trial.
his was an evaluation of the ability of the Chronicle device
Medtronic Inc., Minneapolis, Minnesota), an implantable
emodynamic monitoring system (3), to guide the manage-
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June 7, 2005:24B–9B ACC 2005 Annual Session Highlightshis was a randomized, single-blind trial of the device,
hich utilizes an indwelling lead in the right heart for
easuring filling pressures. The device continuously records
n estimate of pulmonary arterial diastolic (ePAD) pressure
s a surrogate for the pulmonary capillary wedge pressure. It
lso records right ventricular systolic and diastolic pressures.
he COMPASS-HF study enrolled 274 patients with New
ork Heart Association (NYHA) functional class III to IV
F symptoms at 28 centers. The study design required
atients to transmit data weekly from their devices. The
atients were randomized such that the HF physician caring
or them either received the data or was blocked from
eceiving the data. Patients were blinded to their treatment
trategy, although their physicians were not. There were 134
nd 140 patients, respectively, in the groups, and the efficacy
nd point used was the composite of hospitalization, emer-
ency room visit, or clinic visit that required intravenous
herapy. In the COMPASS-HF study, the primary end
oint did not reach statistical significance in the study
opulation as a whole. However, when patients with
YHA functional class IV HF were removed from the
nalysis, there was a 33% reduction in the occurrence of the
omposite end point when therapy was guided by the
hronicle device versus when data was blocked (p 0.035).
At the late-breaking clinical trials sessions, Dr. Feldman
nd colleagues presented the results of the PEECH (Pro-
pective evaluation of EECP in heart failure) trial. This was
prospective evaluation of enhanced external counterpulsa-
ion (EECP) in patients with congestive HF. For this trial,
87 subjects were randomized to optimal medical care with
r without 35 sessions of EECP. Whereas EECP may have
enefit in ischemic heart disease by improving diastolic
oronary artery perfusion, it also reduces afterload and may
hereby provide benefit in nonischemic disease. For this
eason, the PEECH trial included patients with either
schemic or nonischemic HF. At the end of the treatment
eriod, the average exercise time was improved by 25 s in
igure 1. Distribution of Cardiac Function and Heart Failure abstract
ubmissions by subtopic.he EECP-treated group, but worsened by 10 s in the Bon-EECP group (p 0.013). The Minnesota Living with
eart Failure score was better in the EECP group at one
eek and three months of treatment, but there was no
ignificant difference in the quality-of-life score at six
onths.
There was a late-breaking trial using continuous positive
irway pressure (CPAP) for the treatment of patients with
o-existing HF and central sleep apnea. Dr. Bradley pre-
ented the study results, pointing out that “central sleep
pnea is very common in HF and is associated with a
ubstantially higher death rate.” The study enrolled 258 HF
atients from 11 centers, all of whom had central sleep
pnea. The average EF in the study group was 24.5%, and
atients were randomized to either nocturnal CPAP or no
PAP for the two-year study period. The results showed
hat patients in the CPAP group had decreases in their
pnea-hypopnea indexes and decreases in circulating nor-
pinephrine levels. They also had increases in EF from
4.8% to 27.3%. After two years of CPAP treatments,
owever, no significant difference was seen between the
roups in terms of hospitalization rates for HF, quality-of-
ife results, exercise test results, or atrial natriuretic peptide
evels. The investigators cautioned that the results should
ot be extrapolated to HF patients with obstructive sleep
pnea because the study only enrolled those with central
leep apnea.
EATURED POSTERS
arious highly scored and very well-received abstracts were
resented as featured posters.
atriuretic peptides. One presentation used plasma levels
f brain natriuretic peptide (BNP) to guide therapy for HF.
his was presented by Dr. Jourdain and colleagues from
rance and involved 220 patients at 21 sites (4). All patients
ad NYHA functional class II to IV symptoms and systolic
ysfunction with left ventricular EFs 45%. Patients were
andomized to either standard care or to a strategy that used
lasma BNP levels to guide treatment. Patients had
onthly visits for three months and then one visit every four
onths thereafter. The BNP levels were checked, and
alues 100 pg/ml triggered an increase in HF medical
herapy. The median follow-up time was 15 months, and
he investigators found fewer total events (hospitalizations
nd deaths) in the group that had BNP-guided therapy (25
vents vs. 57 events; p 0.001). Improvement in event-free
urvival is shown graphically in Figure 2.
Treatment with BNP was also the subject of a featured
oster titled “B-Type Natriuretic Peptide Infusion Improves
ystolic Dysfunction and Attenuates Ventricular Remodel-
ng in an Experimental Model of Myocardial Infarction”
resented by Dr. Xydas and his group from Columbia
niversity and Scios Inc. (5). For this work, MI was
nduced by coronary artery ligation in rats. The rats were
hen treated with continuous infusions of saline, low-dose
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ACC 2005 Annual Session Highlights June 7, 2005:24B–9Bhen housed for an additional seven weeks, after which time
emodynamic assessments were made. The high-dose BNP
nfusion was associated with myocardial protection as evi-
enced by better fractional shortening, better left ventricular
nd-diastolic pressure, and improved force development at
he end of the study (Fig. 3). This suggests a direct effect of
ntravenous BNP to minimize the adverse ventricular re-
odeling that occurs in the short term following MI.
tem cells. There were several featured posters in the area
f stem cells. One presented by Dr. Na and his group from
eoul, Korea, examined autologous peripheral blood stem
ells as treatment for acute MI (6). These investigators used
n intravenous infusion of granulocyte colony-stimulating
actor (GCSF) to mobilize endogenous stem cells. The
tudy involved 42 patients with acute MI who were under-
oing primary percutaneous intervention. The patients were
andomized into three groups. The first group received a
our-day infusion of GCSF, and then peripheral stem cells
ere isolated by apheresis and administered to the patient
y intracoronary infusion. The second group received only
he four-day infusion of GCSF, and the third group
eceived vehicle alone. The investigators showed functional
mprovement at one year in the group that was treated with
ntracoronary infusion of autologous peripheral blood stem
ells. A significant increase occurred in EF, from 48.9% to
6.7% (p  0.003). There was also a significant improve-
ent in myocardial perfusion by single-photon emission
omputed tomography (SPECT) imaging, with an average
efect of 12.7% being reduced to 7.4%. No improvement
as seen in the groups treated with GCSF infusion alone or
ehicle alone. This suggests that peripheral stem cell mobi-
ization (with GCSF) and targeting of the cells to the
yocardium via direct coronary artery infusion may both be
ecessary steps to achieve clinical benefit.
A featured poster in the area of cardiac transplantation
lso studied peripheral blood stem cells. Dr. Yamani and the
igure 2. Curves showing that event-free survival is better in heart failure
atients whose therapy is guided by plasma brain natriuretic peptide (BNP)
evels. Reprinted from Jourdain et al. (4) with permission.roup from Cleveland evaluated the effect of peri- Aransplant ischemic injury on endogenous mobilization of
eripheral blood stem cells to the allografted heart (7).
hese researchers reported on their collection of 114
ale patients, all of whom had received heart transplants
rom female donors. Of the 114 recipients, 26 had
schemic injury on their initial heart biopsy, and they were
ermed the “ischemic group.” Eighty-eight did not, and they
ere called the “control group.” At one week from cardiac
ransplant, Y-chromosome–containing nuclei were signifi-
antly increased in the 26-patient ischemic group at a level
igure 3. Hemodynamic parameters in post-myocardial infarction (MI)
nimals are best when the rats are acutely treated with a seven-day
ontinuous infusion of high-dose brain natriuretic peptide (BNP) (cross-
atched bars), as compared to infusion with saline (empty bars) or
ow-dose BNP (ruled bars). The hemodynamics were measured 8 weeks
fter the experimental MI and 7 weeks after completion of the infusion.
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June 7, 2005:24B–9B ACC 2005 Annual Session Highlightsf 0.68%, versus Y-chromosome–containing nuclei in the
ontrol group at only 0.04%. The investigators performed
ollow-up studies at one year and found that Y-
hromosome–containing nuclei were increased to 1.25% in
he ischemic group as compared to 0.08% in the control
roup. These results suggest that circulating peripheral
lood stem cells are being mobilized to the myocardium at
much greater rate in hearts that are insulted by ischemia.
he research team also demonstrated that these mobilized
tem cells persist in the heart muscle for at least one year.
nherited cardiomyopathies. A featured poster in the area
f hypertrophic cardiomyopathy was presented by Dr.
algimigli and colleagues from Leiden, the Netherlands (8).
hese investigators used conductance catheters to record
ressure-volume loops at the time of percutaneous alcohol
eptal ablation. Eleven consecutive patients with hypertro-
hic obstructive cardiomyopathy were treated with alcohol
eptal ablation, and the hemodynamics were followed in real
ime. The researchers found that the alcohol septal ablation
rocedure acutely improved the end-systolic volume (35
l¡ 49 ml), acutely reduced the EF (74%¡ 59%), acutely
mproved the minimum dP/dt (1,681 mm Hg/s ¡
1,346 mm Hg/s), reduced the end-systolic pressure (163
m Hg¡ 124 mm Hg), reduced the end-diastolic pressure
24 mm Hg ¡ 16 mm Hg), and improved the pressure
alf-time (43 ms¡ 34 ms). These changes occurred rapidly
nce the alcohol was infused.
A featured poster was presented in the area of arrhyth-
ogenic right ventricular dysplasia (or arrhythmogenic right
entricular cardiomyopathy [ARVC]). It was presented by
r. Rampazzo and her colleagues from Padua, Italy, and
ouston, Texas (9). These investigators performed muta-
ional screening in a 4-generation, 38-member family that
arried the diagnosis of ARVC. The team then extended
he study to 30 other unrelated patients who carried the
iagnosis. The analyses identified two different mutations in
he gene for transforming growth factor 3. In the large
edigree the defect was identified in the 5= upstream region
f the gene, and in one of the 30 unrelated patients a defect
n the 3= untranslated region of the gene was found. These
utations may cause aberrant regulation of the transform-
ng growth factor 3 gene. Aberrant regulation of this gene
ay be directly disease-causing, because transforming
rowth factor 3 is known to be involved in the regulation
f cardiac fibrosis and cell-to-cell adhesion.
RAL SESSIONS
arious abstracts presented at the oral sessions received
ubstantial interest both in their sessions and from the
raders of the abstracts.
nimal models. One oral presentation on “Experimental
odels of Heart Failure” evaluated messenger ribonucleic
cid (mRNA) expression and protein levels for GCSF in
ogs with HF. These results were reported by Dr. Huang
nd colleagues from Detroit, Michigan (10). Heart failure Was produced by intracoronary microembolization, and
hese dogs were compared against normal dogs. In the
yocardium of the HF dogs, the mRNA for GCSF was
ncreased from 24 to 37 arbitrary units, and the protein
xpression was increased as well (p  0.05). The investiga-
ors postulate that the increase in GCSF production may
epresent an intrinsic adaptive mechanism that stimulates
ovement of primitive bone marrow cells to the injured
yocardium.
A presentation that was made in the session on “Novel
echanisms of Cardiomyopathy” related to doxorubicin
ardiotoxicity. Panjrath et al. (11) showed that rats fed
arbonyl iron, in addition to receiving intraperitoneal or
ntravenous doxorubicin, had much worse survival than rats
eceiving doxorubicin alone. The rats receiving dietary iron
nd doxorubicin had a death rate of 45%, whereas the death
ate with doxorubicin alone was 12% and no deaths occurred
ith dietary iron alone. Characteristic findings of myocyte
njury on electron microscopy paralleled the mortality data,
nd the researchers concluded that dietary iron loading
ncreases the cardiotoxicity produced by doxorubicin, prob-
bly through a free radical injury mechanism.
uman HF studies. In the oral session on “Revasculariza-
ion and Heart Failure,” there was a presentation by Dr.
uszman and his group from Poland that focused on percu-
aneous revascularization versus surgical revascularization in
atients with depressed left ventricular EF (12). Titled “Re-
ascularization in Ischemic Heart Failure Trial” (REHEAT),
his was a prospective case-control study, with 52 patients in
he percutaneous coronary intervention (PCI) group and 51
atients in the bypass surgery group. Investigators evaluated
he 12-month survival and found it to be 100% in the PCI
roup and 94% in the bypass group, with major adverse
vents occurring at 21% and 11% in the two groups,
espectively. The EF improved from 32% to 39% in the PCI
roup, with a similar improvement in the bypass group. The
eam concluded, relevant to the ongoing, somewhat similar
rial in the U.S. called STICH (Surgical Treatment of
schemic Heart Failure), that treating ischemic heart failure
sing a PCI strategy versus a bypass surgery strategy leads to
imilar outcomes at 12 months.
There was an oral session on “Heart Failure and the
idney.” An abstract presented in this session involved
ontinuous recording of hemodynamic responses in dialysis
atients with impaired left ventricular function. This was
resented by a group from Sweden and involved nine
atients with end-stage kidney disease who were on chronic
ntermittent hemodialysis (13). The patients had EFs of
0% to 50%, and all received implantable hemodynamic
onitoring (Chronicle) devices. The investigators showed
hat gradual increases occurred in the right ventricular
ressure and ePAD pressure as the time since hemodialysis
reatment increased (Fig. 4).
In the oral session on “Heart Failure and Statins” there
as a report titled “Statins Improve Survival in Patients
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ACC 2005 Annual Session Highlights June 7, 2005:24B–9Bhis was submitted by Jaganmohan and Khurana (14) from
hreveport, Louisiana, and was a retrospective, case-control
tudy of over 30,000 veterans from Louisiana, Mississippi,
exas, and Arkansas who carried the diagnosis of congestive
F. The mean age of the cohort was 62.7 years, and 61%
ere on statins. Thirty-one percent of the patients had
schemic heart disease. A Cox proportional hazards model
as used to adjust for the covariates of age, gender,
moking, ischemic heart disease, diabetes, and beta-blocker
se. The researchers showed improved survival in the cohort
ho received statin therapy, with an adjusted hazard ratio
HR) for statin use of 0.90 (95% confidence interval [CI] of
.88 to 0.92). The unadjusted HR favored statin use even
ore. Mean survival was 22.8  0.2 months in the statin
roup and 17.2  0.2 months in the non-statin group. The
nvestigators concluded that the beneficial effect of statin
herapy is independent of traditional coronary risk factors
nd is independent of whether the HF is ischemic in origin.
his suggests a direct beneficial effect of statin therapy in
F, perhaps via an anti-inflammatory mechanism.
xercise and cardiac rehabilitation. In the area of exer-
ise physiology, an oral presentation studied improvement
n functional capacity and heart rate recovery after clinically
ndicated phase II cardiac rehabilitation (15). These inves-
igators from Cleveland, Ohio, studied 692 consecutive
atients referred for cardiac rehabilitation. Patients were
lassified as either having good functional capacity at entry
group 1), low functional capacity that improved to good
unctional capacity after completing phase II cardiac reha-
ilitation (group 2), or low functional capacity that re-
ained low despite the cardiac rehabilitation program
group 3). Patients were then followed over several years,
nd survival curves were generated (Fig. 5). The patients
ho had good functional capacity at enrollment had the best
igure 4. Gradual rise in filling pressures as assessed by implanted
emodynamic monitoring device in patients with chronic, end-stage
idney disease on hemodialysis. Values were recorded the first, second, and
hird nights after hemodialysis therapy. Adapted from Linde et al. (13)
ith permission. PA  pulmonary arterial; RV  right ventricular.urvival. Those who had low functional capacity that im-
roved with cardiac rehabilitation had intermediate survival,
nd those who had persistently low functional capacity
espite completing the cardiac rehabilitation program had
he worst survival.
UMMARY
he ACC 2005 Scientific Sessions showed many new and
xciting developments in the area of Cardiac Function and
eart Failure. This is a credit to the many invited speakers
ho presented symposia and special sessions in this area, the
11 groups who submitted abstracts of their original re-
earch, the 71 reviewers who evaluated the submissions, and
he 281 presenters who prepared their research for oral and
oster presentations. Cardiac Function and Heart Failure
ontinues to be one of the larger sections within the ACC
cientific Sessions. Similar to a positive feedback loop, it is
he enthusiasm for this topic that drives the novel research
hat is presented, and the research that is presented in turn
rives ongoing enthusiasm for this topic.
eprint requests and correspondence: Dr. Daniel F. Pauly, P.O.
ox 100277, Division of Cardiovascular Medicine, Room M421,
niversity of Florida College of Medicine, 1600 S.W. Archer
oad, Gainesville, Florida 32610. Email: paulydf@medicine.
fl.edu.
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